This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

SHORT REPORT

Quality of life, pain and use of analgesic, anxiolytic and antidepressant medication, in people living in care homes

Jemima T. Collins^{1,2}, Lisa Irvine³, Pip Logan¹, Katie Robinson^{1,4}, Erika Sims⁵, Adam L. Gordon^{1,2,6}

Address correspondence to: Jemima T. Collins. Email: jemima.collins@nottingham.ac.uk, mszjtc@exmail.nottingham.ac.uk

Abstract

Background: People living in care homes often have problems with pain, anxiety and depression. Whether being on analgesia, anxiolytics or antidepressants has any bearing on pain severity and quality of life (QoL) in this population, requires further investigation.

Objectives: (i) to examine the relationship between pain, anxiety and depression and medication use in care home residents and (ii) to compare those on medications to treat pain, anxiety and depression, and those who were not, and associations with pain severity and overall QoL.

Methods: This was a secondary analysis of a randomised controlled trial testing a falls prevention intervention in care homes. We recorded pain, anxiety and depression, QoL measurements and prescribed medication use.

Results: In 1589 participants, the mean age was 84.7 years (±9.3 SD), 32.2% were male and 67.3% had a diagnosis of dementia. 54.3% and 53.2% of participants had some level of pain and anxiety or depression respectively, regardless of prescribed medication use. There was a direct association between pain severity and being on any analgesia, opioid analgesia, and antidepressants, but no associations between pain severity and use of paracetamol and anxiolytics. QoL was best for residents with no pain and not on any analgesia, anxiolytics or antidepressants and worst for those with moderate-extreme pain and taking at least two of these classes of medications.

Conclusion: Many care home residents live with pain, anxiety and depression. Addressing residents' pain may also increase their quality of life, but using medication alone to reach this goal may be inadequate.

Keywords: pain; analgesia; care homes; quality of life; older people

Key Points

- Over 50% of people living in UK care homes have pain.
- There is a significant association between the severities of pain and anxiety and depression in people living in care homes
- Higher pain severity was associated with taking any analgesia, opioid analgesia and antidepressants.
- Quality of life was lowest for care home residents with greatest pain and was on ≥2 analgesia, antidepressants or anxiolytics.

¹Centre for Rehabilitation and Ageing, Injury, Recovery and Inflammation Sciences Academic Unit, School of Medicine, the University of Nottingham, Nottingham, UK

²University Hospitals Derby and Burton NHS Trust, Derby, UK

 $^{^3}$ Centre for Research in Public Health and Community Care, University of Hertfordshire, Hatfield, UK

⁴Research and Innovation, Nottingham University Hospitals NHS Trust, Nottingham, UK

⁵Norwich Medical School, University of East Anglia, Norwich, UK

⁶Applied Research Collaboration-East Midlands (ARC-EM), Nottingham, UK

Introduction

Older people living in care homes have high care needs due to cognitive and physical disabilities [1, 2]. There are \sim 11 000 care homes in the UK providing full time care for >400 000 residents who have dependency, and whose care needs cannot be met at home [3].

Pain is sub-optimally assessed and treated, in ageing populations [4, 5]. An estimated 40%–50% of older people living in care homes have troublesome pain [6] and this proportion can be as high as 79% in those living with dementia and at the end of life [7, 8]. Pain is closely associated to, and frequently coexists with, neuropsychiatric symptoms such as anxiety, depression and behavioural symptoms. A number of studies have considered whether it is beneficial to use analgesics to treat common neuropsychiatric symptoms, anxiety and depression and of using anxiolytics and antidepressants to treat pain. However, evidence of efficacy has been mixed [9–12].

Health-related quality of life (QoL) is one of the most important measurable parameters in the evaluation of pain management success, and validated scales for care home residents include questions regarding pain, feelings and physical functioning [13, 14]. Neuropsychiatric symptoms may be caused by underlying pain, directly affect both pain and QoL, or mediate the relationship between pain and QoL [15–17]. This study set out to examine the relationship between pain, anxiety and depression in this population. Moreover, we sought to evaluate whether there was any difference between the pain levels and overall QoL of care home residents who were on medications to treat pain, anxiety and depression, compared with those who were not.

Methods

Study design, setting, sample size and intervention

We performed a cross-sectional secondary analysis of data collected from the Falls in Care Homes (FinCH) trial [18]. FinCH was a multicentre, parallel, 1:1 cluster randomised controlled trial (RCT) to test the Guide to Action Care Home (GtACH) programme (a risk assessment and decision support tool which provided falls prevention training and resources to all care home staff) compared with standard care. The FinCH RCT was given ethical approval by the Yorkshire and Humber–Bradford Leeds research ethics committee (REC 16/YH/0111) and recruited 1657 participants from 84 care homes between November 2016 and January 2018 [19]. Its main aim was to determine both clinical and cost effectiveness of GtACH compared with usual care [18].

Outcome measurements

i) Quality of Life

DEMQOL-P is a 31-item questionnaire completed by the primary caregiver as a proxy for a person living with dementia [14]. Scores range from 31 to 124, with higher scores reflecting better health-related QoL. DEMQOL-P was developed specifically for people living with dementia but is widely used and accepted to measure QoL in all care home residents [14, 20]. For the purposes of this study, QoL was defined as baseline DEMQOL-P scores.

ii) Pain severity

Pain measurements were extracted from the corresponding domains in the EuroQoL-5 domain-5 level-Proxy (EQ-5D-5L-P) [21] questionnaires completed as part of the study. There are 5 levels for pain: 1 = No pain or discomfort; 2 = Slight pain or discomfort; 3, 4 and 5 = Moderate, Severe and Extreme pain or discomfort, respectively. Because we analysed subdomains of the EQ-5D-5L-P for pain and anxiety we did not use the overall EQ-5D-5L-P score as a measure of QoL in this secondary analysis.

Exposure

The exposure in this study is defined as types of prescribed medications. Medication use was noted from care home medication records. For this secondary analysis, we specifically focused on medications classified in Chapter 4 of the British National Formulary [22] as analgesia, anxiolytics and antidepressants (collectively referred to as 'medication' hereafter).

Covariates

The covariates in this study are defined as residents' age, sex, dementia diagnosis, Barthel index and severity of anxiety or depression as measured in the EQ-5D-5L-P [21]. There are five levels for anxiety and depression: 1 = Not anxious or depressed; 2 = Slightly anxious or depressed; 3, 4 and 5 = Moderately, Severely or Extremely anxious or depressed, respectively.

Data extraction and statistical analysis

All data extracted from the main FinCH dataset for the purposes of this secondary analysis were baseline measurements. The rationale for this was to enable cross-sectional analysis of pain, depression and anxiety levels of care home residents, correlations with medications and QoL, and to reduce longitudinal data missingness due to attrition.

Descriptive statistics were expressed as absolute and relative frequencies for discrete variables, and means and standard deviation for continuous variables. The distribution of each variable was assessed for normality with the Kolmogorov–Smirnov and the Shapiro–Wilks tests. We used the Pearson correlation test to evaluate for between group differences of prevalence for categorical data, and Kruskal Wallis test for differences between groups of non-parametric continuous data. To visually assess the difference for primary outcomes (QoL and pain severities), a scatterplot was used. IBM SPSS statistics (version 28) was used for statistical analysis.

Table 1. Characteristics and descriptive statistics of care home residents with complete pain data included in the study

	<u></u>						
	All Residents (n = 1589)	No Pain (n = 726)	Mild Pain n = 508)	Moderate Pain (n = 278)	Severe Pain (n = 60)	Extreme Pain (n = 17)	Pearson's correlation coefficient (r), p-value
Age in years, Mean \pm SD §	84.7 ± 9.3	83.8 (9.4)	85.3 (8.8)	85.6 (9.8)	86.6 (7.5)	84.7 (7.5)	r 0.081,
Sex							p = 0.001
Males, n (%)	512 (32.2)	253 (34.8)	161 (31.7)	76 (27.3)	42 (70)	13 (76.5)	r - 0.058
Females, n (%)	1077 (67.8)	473 (65.2)	347 (68.3)	202 (72.7)	18 (30)	4 (23.5)	p = 0.021
Barthel Index Mean ± SD [§]	8.6 ± 6.0	9.4 (6.1)	8.1 (5.8)	7.8 (6)	6.3 (5.2)	6.2 (6.3)	r - 0.14
Dementia diagnosis, n (%)							p < 0.001
No	518 (32.6)	202 (27.8)	169 (33.3)	111 (39.9)	33 (55)	3 (17.6)	r - 0.108
Yes	1070 (67.3)	524 (72.2)	338 (66.7)	167 (60.1)	27 (45)	14 (82.4)	p < 0.001
Missing	1 (0.1)						
Presence of anxiety/depression,							
EQ5D5L, n (%)							
Not anxious/depressed	744 (46.8)	465 (64.2)	180 (35.4)	81 (29.1)	12 (20)	6 (35.3)	r 0.309
Slightly anxious/depressed	502 (31.6)	176 (24.3)	206 (40.6)	93 (33.5)	24 (40)	3 (17.6)	p < 0.001
Moderately anxious/depressed	235 (14.8)	55 (7.6)	89 (17.5)	75 (27)	13 (21.7)	3 (17.6)	_
Severely anxious/depressed	68 (4.3)	19 (2.6)	21 (4.1)	19 (6.8)	7 (11.7)	2 (11.8)	
Extremely anxious/depressed	38 (2.4)	9 (1.2)	12 (2.4)	10 (3.6)	4 (6.7)	3 (17.6)	
Missing	2 (0.1)						
Number of prescribed analgesic							
medications, n (%)							
0	768 (48.3)	396 (54.5)	235 (46.3)	120 (43.2)	14 (23.3)	3 (17.6)	r 0.144
1 or more	821 (51.7)	330 (45.5)	273 (53.7)	158 (56.8)	46 (76.7)	14 (82.4)	p < 0.001
Paracetamol use,							_
n (%)							
No	1002 (63.1)	470 (64.7)	312 (61.4)	182 (65.5)	29 (48.3)	9 (52.9)	r 0.04
Yes	587 (36.9)	256 (35.3)	196 (38.6)	96 (34.5)	31 (51.7)	8 (47.1)	p = 0.110
Opioid Medication use, n (%)							
0	1183 (74.4)	598 (82.4)	377 (74.2)	179 (64.4)	22 (36.7)	7 (41.2)	r 0.231
1 or more	406 (25.6)	128 (17.6)	131 (25.8)	99 (35.6)	38 (63.3)	10 (58.8)	p < 0.001
Anxiolytic Medication use, n (%)							
0	1408 (88.6)	652 (89.8)	442 (87)	246 (88.5)	53 (88.3)	15 (88.2)	r 0.021
1 or more	181 (11.4)	74 (10.2)	66 (13)	32 (11.5)	7 (11.7)	2 (11.8)	p = 0.413
Antidepressant Medication use, n (%)							
0	878 (55.3)	422 (58.1)	285 (56.1)	140 (50.4)	25 (41.7)	6 (35.3)	r 0.084
1 or more	711 (44.7)	304 (41.9)	223 (43.9)	138 (59.6)	35 (58.3)	11 (64.7)	p < 0.001

Results

Out of 1657 participants from the original FinCH dataset, 1589 residents (95.9%) with complete baseline pain data were included into this study. The average (SD) participant age was 84.7 years (± 9.3), 32.2% were male and 67.3% had a diagnosis of dementia. The average (SD) Barthel Index was 8.6 (6.0) (Table 1).

A total of 54.3% had pain and 53.2% had anxiety or depression. There was a significant correlation between severity of pain, and severity of anxiety or depression (Pearson's r = 0.309). In those not taking regular analgesia, 48% had some level of pain. In those taking one or more analgesic, 59.9% had some level of pain. There was an association between pain severity and being prescribed any analgesic, opioids and antidepressants, but no associations between pain severity and use of paracetamol or anxiolytics.

The mean (SD) DEMQOL-P values in the different pain severity categories were 103.9 (11.9), 98.7 (14.2) and 94.6

(15) for groups of no pain, mild pain and moderate to extreme pain, respectively. Within the no pain and mild pain categories, people who were on two or more classes of medication had significantly worse QoL compared with those on 0 or 1 class only, but in the moderate to extreme category there was no significant difference in QoL stratified by medication use (Figure 1). Supplementary Tables 1 and 2 contain regression analyses in which pain is found to be significantly inversely associated with QoL, even after adjusting for confounding factors.

Discussion

Pain is a common problem in ageing populations. This secondary analysis of a large randomised controlled trial dataset of care home residents adds insight into medication use in this population and associations with pain. Higher pain severities were associated with higher medication use, in keeping with previous literature [23]. Although there is an

Quality of Life in care home residents according to pain categories and stratified by medication use




Figure 1. Quality of life (DEMQOL-P score) of care home residents, comparing differences between groups not prescribed any analgesia, anxiolytics or antidepressants, only prescribed one class of analgesia, anxiolytics or antidepressants, or prescribed both analgesia and anxiolytic or antidepressant; stratified according to pain severity. Kruskal Wallis test used to compare between groups differences.

association between increased use of opioids and increased pain, this does not necessarily mean that opioids are not effective in residents with higher levels of pain. It may be that their pain was much higher to begin with, and the use of opioids has mitigated this severity. Paracetamol is often used in combination with other stronger analgesics and likely contributes to overall analgesia effectiveness.

There is modest evidence that taking antidepressant, anxiolytic and analgesic medications may improve QoL [24–26] but this is less clear in care home residents [10]. In this study, residents on two or more medications from analgesia, antidepressant and anxiolytic categories with moderate to extreme pain had the lowest QoL. This data suggests that pain is important in influencing QoL, regardless of medication use. This emphasizes that initiating and continuing these medications should be based on clinical indication, ongoing need, and the risk and benefit profile for the individual.

Over 50% of care home residents had some level of pain, in keeping with other literature suggesting that undertreatment of pain in care home residents is due to underrecognition of pain [27]. Assessment of medication efficacy could be improved by care home staff intentionally assessing pain with validated assessment tools [28]. Clinicians may then review medications, and others involved in the residents' care such as the Activity Coordinator may suggest non-pharmacological approaches such as tailored pain interventions and music therapy [29].

Strengths and limitations

This study effectively repurposed individual participant data from a large RCT conducted in UK care homes to compare QoL measures and medication use, providing insights not typically available through administrative data [30]. These care homes were 'research ready' and thus might be more

proactive than other facilities in performing medication reviews. All data were taken at baseline and as such there was very little missing data. Due to the cross-sectional, observational nature of this study, the cause and effect relationship could not be established and thus translation to causality remains speculative. A further limitation was that we did not note doses, frequencies or as required medication use as this was not fully recorded. 'Medication use' referred to prescribed analgesia, anxiolytic or antidepressant medication only; full compliance was assumed but not confirmed. Noting the reasons for pain may have given clarity to, for example, the effectiveness of medication taken for neuropathic pain and/or depression. Access to these data would have strengthened the accuracy of our findings.

Conclusion

This study highlights that a substantial proportion of care home residents live with pain. Nearly half of those not prescribed any analgesia had pain, representing a subset of residents who almost certainly would benefit from either non-pharmacological and/or pharmacological interventions. Addressing residents' pain may also increase quality of life, but using medication alone to reach this goal is likely to be inadequate.

Acknowledgements: We wish to acknowledge Dr Allan Clark, Statistician and Dr Giulia Ogliari, Epidemiologist for their support with data analysis.

Supplementary Data: Supplementary data mentioned in the text are available to *subscribers in Age and Ageing* online.

Declaration of Conflicts of Interest: ALG has received honoraria from Gilead Sciences and Pfizer Inc. for consultancy work on COVID-19 infection in care homes. All other authors declare that they have no conflicts of interest.

Declaration of Sources of Funding: This study presents independent research supported by the United Kingdom National Institute for Health and Care Research (NIHR) (grant award number 13/115/29) Nottingham Biomedical Research Centre (BRC). J.T.C. was funded by the NIHR in her role as Academic Clinical Lecturer. A.L.G. and P.L. are NIHR Senior Investigators and are also part funded by the NIHR Applied Research Collaboration-East Midlands (ARC-EM). K.R. is funded by an NIHR Advanced Fellowship (NIHR300115).

The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

References

1. Moore KL, Boscardin WJ, Steinman MA *et al.* Patterns of chronic co-morbid medical conditions in older residents of U.S. nursing homes: Differences between the sexes and across the agespan. *J Nutr Health Aging*. 2014;**18**:429–36.

Quality of life, pain and medication

- 2. Bethell J, Aelick K, Babineau J *et al.* Social connection in long-term care homes: A scoping review of published research on the mental health impacts and potential strategies during COVID-19. *J Am Med Dir Assoc.* 2021;22:228–237.e25.
- Competition and Markets Authority. Care Home Market Study: Summary of the Final Report. UK: Crown Office London, 2017. Available online at https://www.gov.uk/gove rnment/publications/care-homes-market-study-summary-of-final-report/care-homes-market-study-summary-of-final-report (26 April 2024, date last accessed).
- Collins JT, Harwood RH, Cowley A et al. Chronic pain in people living with dementia: Challenges to recognising and managing pain, and personalising intervention by phenotype. Age Ageing. 2023;52:afac306.
- Collins JT, Walsh DA, Gladman JRF et al. The difficulties of managing pain in people living with frailty: The potential for digital phenotyping. *Drugs Aging*. 2024;41:199–208.
- 6. Björk S, Juthberg C, Lindkvist M et al. Exploring the prevalence and variance of cognitive impairment, pain, neuropsychiatric symptoms and ADL dependency among persons living in nursing homes; a cross-sectional study. BMC Geriatr. 2016;16:154.
- Atee M, Morris T, Macfarlane S et al. Pain in dementia: Prevalence and association with neuropsychiatric behaviors. J Pain Symptom Manage. 2021;61:1215–26.
- **8.** Helvik AS, Bergh S, Tevik K. A systematic review of prevalence of pain in nursing home residents with dementia. *BMC Geriatr*. 2023;**23**:641.
- Erdal A, Flo E, Aarsland D et al. Efficacy and safety of analgesic treatment for depression in people with advanced dementia: Randomised, multicentre, double-blind, placebo-controlled trial (DEP.PAIN.DEM). Drugs Aging. 2018;35:545–58.
- **10.** van Dam PH, Achterberg WP, Husebo BS *et al.* Does paracetamol improve quality of life, discomfort, pain and neuropsychiatric symptoms in persons with advanced dementia living in long-term care facilities? A randomised double-blind placebo-controlled crossover (Q-PID) trial. *BMC Med.* 2020;**18**:407.
- **11.** Ferreira GE, Abdel-Shaheed C, Underwood M *et al.* Efficacy, safety, and tolerability of antidepressants for pain in adults: Overview of systematic reviews. *BMJ*. 2023;**380**:e072415.
- **12.** Birkinshaw H, Friedrich CM, Cole P *et al.* Antidepressants for pain management in adults with chronic pain: A network meta-analysis. *Cochrane Database Syst Rev.* 2023;**2023**:CD014682.
- **13.** Usman A, Lewis S, Hinsliff-Smith K *et al.* Measuring health-related quality of life of care home residents: Comparison of self-report with staff proxy responses. *Age Ageing*. 2019;**48**:407–13.
- **14.** Hughes LJ, Farina N, Page TE *et al.* Adaptation of the DEMQOL-proxy for routine use in care homes: A cross-sectional study of the reliability and validity of DEMQOL-CH. *BMJ Open.* 2019;**9**:e028045.
- **15.** Husebo BS, Ballard C, Sandvik R *et al.* Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: Cluster randomised clinical trial. *BMJ*. 2011;**343**:d4065.
- **16.** Resnick B, Galik E, Kolanowski A *et al.* The relationship between pain, function, Behavioral, and psychological symptoms of dementia and quality of life. *Pain Manag Nurs*. 2022;**23**:55–61.

- **17.** Landi F, Onder G, Cesari M *et al.* Pain and its relation to depressive symptoms in frail older people living in the community: An observational study. *J Pain Symptom Manage*. 2005;**29**:255–62.
- **18.** Logan PA, Horne JC, Gladman JRF *et al.* Multifactorial falls prevention programme compared with usual care in UK care homes for older people: Multicentre cluster randomised controlled trial with economic evaluation. *BMJ*. 2021;**375**:e066991.
- 19. Logan P, McCartney K, Armstrong S et al. Evaluation of the guide to action care home fall prevention progamme in care homes for older people: Protocol for a multi-Centre, single blinded, cluster randomised controlled trial (FinCH). East Midlands Research into Ageing Network (EMRAN) Discussion Paper Series. 2019:1–44. www.nottingham.ac.uk/emran/docu ments/issue-25-emran-feb-2019.pdf.
- **20.** Edvardsson D, Baxter R, Corneliusson L *et al.* Advancing long-term care science through using common data elements: Candidate measures for care outcomes of personhood, well-being, and quality of life. *Gerontol Geriatr Med.* 2019;**5**:2333721419842672.
- **21.** Devlin NJ, Shah KK, Feng Y *et al.* Valuing health-related quality of life: An EQ-5D-5L value set for England. *Health Econ.* 2018;**27**:7–22.
- **22.** Joint Formulary Committee. *British National Formulary [Internet]*. LondonAvailable from:: British Medical Association and Royal Pharmaceutical Society of Great Britain, [updated 2024 Mar 12; cited 2024 Mar 27]. https://www.medicinescomplete.com/#/browse/bnf.
- Eriksen J, Sjøgren P, Bruera E et al. Critical issues on opioids in chronic non-cancer pain: An epidemiological study. Pain. 2006;125:172–9.
- **24.** Caruso R, Ostuzzi G, Turrini G et al. Beyond pain: Can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta-analysis PAIN. 2019;**160**:2186–98.
- **25.** Hofmann SG, Wu JQ, Boettcher H *et al.* Effect of pharmacotherapy for anxiety disorders on quality of life: A meta-analysis. *Qual Life Res.* 2014;**23**:1141–53.
- **26.** Wiesinger T, Kremer S, Bschor T *et al.* Antidepressants and quality of life in patients with major depressive disorder Systematic review and meta-analysis of double-blind, placebo-controlled RCTs. *Acta Psychiatr Scand.* 2023; **147**: 545–60.
- 27. Liu JYW, Leung DYP. Pain treatments for nursing home residents with advanced dementia and substantial impaired communication: A cross-sectional analysis at baseline of a cluster randomized controlled trial. *Pain Med*. 2017;18:pnw242–1657.
- **28.** Smith TO, Harvey K. Psychometric properties of pain measurements for people living with dementia: A COSMIN systematic review. *Eur Geriatr Med.* 2022;**13**:1029–45.
- **29.** Liao YJ, Parajuli J, Jao YL *et al.* Non-pharmacological interventions for pain in people with dementia: A systematic review. *Int J Nurs Stud.* 2021;**124**:104082.
- **30.** Irvine L, Burton J, Ali M *et al.* Data resource profile: the virtual international care homes trials archive (VICHTA). *Int J Popul Data Sci.* 2024;**8**:2161.

Received 29 April 2024; editorial decision 21 August 2024



ID NOW™ PLATFORM

KNOW FASTER SO YOU CAN ACT QUICKER

NOW

Now, you can provide rapid molecular respiratory testing for COVID-19, influenza, RSV and strep A in any acute care setting, where and when it's needed most.



IDNOW APPOT

IMPROVED WORKFLOW with single patient swab for COVID-19 and influenza A & B